Drugs News and Research

RSS

Doctors and scientists form national pain research centre

An expert network of doctors and research scientists is forming the world's first national centre for research into understanding pain in arthritis. Backed by medical research charity the Arthritis Research Campaign and The University of Nottingham, it will aim to improve treatments for arthritis - the most common cause of chronic pain - which affects more than ten million people in the UK.

12 Oct 2009

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Eric Boerwinkle, Ph.D., a professor at The University of Texas Health Science Center at Houston, has received a $26 million federal stimulus grant to lead an effort to pinpoint genetic factors affecting the risk of heart, lung and blood diseases.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Women who take fertility drugs are at greater risk to develop thyroid cancer

Women who take the most common fertility drugs, progesterone and clomiphene, are at a greater risk to develop thyroid cancer than those who don't, according to a study by the Institute of Cancer Epidemiology, Danish Cancer Society.

12 Oct 2009

Three hundred participants sought for world-first study to determine shared biological basis for psychotic illnesses

For the first time, sufferers of schizophrenia and bipolar disorder are being brought together in a major new study investigating the diseases' common genetic causes and manifestations.

11 Oct 2009

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

Recent releases in Global Health

A Lancet comment examines an Affordable Medicines Facility for malaria (AMFm) program to help countries procure subsidized artemisinin-based combination treatments (ACTs).

9 Oct 2009

Scidev.Net examines African Network for Drugs and Diagnosis Innovation

SciDev.Net examines a recent conference in Cape Town, South Africa, where almost "300 researchers and health policymakers from across the continent" came together and approved a 2010-2015 business plan for the the African Network for Drugs and Diagnosis Innovation (ANDI).

9 Oct 2009

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

9 Oct 2009

AST assembles at Capitol Hill to support health care reform for kidney transplant recipients

As Congress wraps up work on health care reform, members of the American Society of Transplantation's (AST) Public Policy Committee arrived on Capitol Hill today to discuss the importance of supporting a health care provision that would ensure kidney transplant recipients continue to receive.

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

AST urges Senate Finance Committee to adopt a health care provision for transplant drug extension

As the Senate Finance Committee prepares to vote on the amended health care reform package, members of the American Society of Transplantation (AST) arrived on Capitol Hill armed with a letter encouraging the Senate to adopt a health care provision that will extend Medicare's coverage of post-transplant drugs, which are critical to maintaining the health of the transplant patient. Immunosuppressive drugs are currently covered for a period of 36 months.

9 Oct 2009

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

In response to new economic and regulatory realities, CytoDyn, Inc. has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS.

9 Oct 2009

Generic medicines and mail-service pharmacies are viable options for reducing health care costs

Many consumers looking for ways to reduce their health care costs are taking potentially dangerous steps such as foregoing prescription drug medications altogether or skipping necessary refills, according to a new survey from Consumer Reports.

9 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

AHF criticizes Pfizer for its current pricing of Selzentry AIDS drug

Responding to today’s news that the Food and Drug Administration (FDA) Antiviral Advisory Committee has approved Pfizer Inc.'s AIDS therapy, Selzentry (maraviroc), for use in therapy-naïve patients, AIDS Healthcare Foundation (AHF) strongly criticized Pfizer for its current pricing of the drug at an Average Wholesale Price (AWP) of $13,767 per-patient per-year—which, if this price remains when use is expanded, would make it the most expensive first-line AIDS drug on the market.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

HST Global announces alliance for R&D of Nutraceutical and Medical Food formulation platform

HST Global, Inc. today announced a strategic R&D alliance with Dr. James W. Forsythe for the research and development of HST’s exclusive Nutraceutical and Medical Food formulation platform.

9 Oct 2009

Ipsen signs exclusive marketing agreement to produce and distribute Braintree's BLI-800 for colonic cleansing

Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group and Braintree Laboratories, Inc., a US-based company specializing in the development, manufacturing and marketing of specialty pharmaceuticals, announced today the signature of an agreement for the exclusive manufacturing, marketing and distribution rights of Braintree’s proprietary formulation BLI-800 in colonic cleansing before colonoscopy, the best diagnostic procedure for colorectal cancer screening.

9 Oct 2009

Clemson bioengineer designing new ways to target drugs

Clemson bioengineer Frank Alexis is designing new ways to target drugs and reduce the chances for side effects.

9 Oct 2009

Drugs News and Research

Doctors and scientists form national pain research centre

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Presentations on efficacy of interferon to combat influenza

Women who take fertility drugs are at greater risk to develop thyroid cancer

Three hundred participants sought for world-first study to determine shared biological basis for psychotic illnesses

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Recent releases in Global Health

Scidev.Net examines African Network for Drugs and Diagnosis Innovation

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

AST assembles at Capitol Hill to support health care reform for kidney transplant recipients

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

AST urges Senate Finance Committee to adopt a health care provision for transplant drug extension

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

Generic medicines and mail-service pharmacies are viable options for reducing health care costs

New soy germ-based ingredient improves menopausal symptoms

AHF criticizes Pfizer for its current pricing of Selzentry AIDS drug

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

HST Global announces alliance for R&D of Nutraceutical and Medical Food formulation platform

Ipsen signs exclusive marketing agreement to produce and distribute Braintree's BLI-800 for colonic cleansing

Clemson bioengineer designing new ways to target drugs

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News